首页> 外文期刊>The Lancet >Randomised vaccine trial of single dose of killed Leishmania major plus BCG against anthroponotic cutaneous leishmaniasis in Bam, Iran.
【24h】

Randomised vaccine trial of single dose of killed Leishmania major plus BCG against anthroponotic cutaneous leishmaniasis in Bam, Iran.

机译:伊朗巴姆市单剂量杀伤性利什曼原虫加卡介苗抗人为性皮肤利什曼病的单剂随机疫苗试验。

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND: A vaccine consisting of a single dose of whole-cell autoclave-killed Leishmania major (ALM) mixed with BCG was assessed in comparison with BCG alone against anthroponotic (human to human transmission) cutaneous leishmaniasis in a randomised double-blind trial in Bam, Iran. METHODS: 3637 schoolchildren, aged 6-15 years, with no history of cutaneous leishmaniasis and no response to a leishmanin skin test, were randomly assigned to receive 1 mg ALM mixed with BCG (n = 1839), or BCG alone (n = 1798). Safety of the vaccine and the incidence of confirmed cases of cutaneous leishmaniasis were followed up for 2 years. FINDINGS: Side-effects were those usually associated with BCG vaccination, but tended to persist longer in the ALM + BCG group. After exclusion of four cases occurring within 80 days of vaccination (one in the ALM + BCG group and three in the BCG group), the 2-year incidence of cutaneous leishmaniasis did not differ significantly between vaccine and BCG groups: 2.8% vs 3.3%, respectively (total cases 112). A sex-stratified analysis showed that in boys the vaccine conferred a protective efficacy of 18% and 78% for the first and second years, respectively--a crude 2-year overall protection of 55% (95% CI 19-75%, p < 0.01). In the first 9 months after vaccination, there was a non-significant excess of cases in the ALM + BCG group (25 vs 16), whereas the incidence of cutaneous leishmaniasis thereafter was significantly reduced in the ALM + BCG group (27 vs 44, p < 0.05). INTERPRETATION: A single dose of ALM + BCG was safe and more immunogenic than BCG alone, as measured by leishmanin skin test. The exact reason for the apparent protective effect of the vaccine in boys is unknown, and may be a chance finding. However, since boys are more exposed to the infection, which is indicated by higher disease prevalence in boys in this study population, the preferential protective effect in boys may have resulted from a greater booster effect produced by repeated exposure to infected sandflies. Booster injections or alternative adjuvants should be tried to improve the potential efficacy of this vaccine.
机译:背景:在Bam的一项随机双盲试验中,与单用BCG相比,评估了由单剂量全细胞高压灭菌的利什曼原虫杀灭性大利什曼原虫(ALM)与BCG混合制成的疫苗,以抗人为(人传人)皮肤利什曼病,伊朗。方法:3637名6-15岁,没有皮肤利什曼病史,对利什曼宁皮肤试验无反应的学童被随机分配接受1 mg ALM与BCG混合(n = 1839)或单独BCG(n = 1798) )。对疫苗的安全性和确诊的皮肤利什曼病病例的发生率进行了2年的随访。结果:副作用通常是与卡介苗接种有关的,但在ALM + BCG组中倾向于持续更长的时间。排除接种后80天内发生的4例病例(ALM + BCG组1例,BCG组3例),疫苗和BCG组的2年皮肤利什曼病发病率无显着差异:2.8%vs 3.3% ,(总共112例)。一项按性别分层的分析表明,在男孩中,该疫苗在第一年和第二年分别提供18%和78%的保护效果-粗略的2年总体保护率为55%(95%CI 19-75%, p <0.01)。在接种疫苗后的前9个月,ALM + BCG组的病例无明显增加(25比16),而此后ALM + BCG组的皮肤利什曼病的发生率显着降低(27比44)。 p <0.05)。解释:单剂量的ALM + BCG比利什曼原皮试验更安全,而且比单独的BCG更具免疫原性。该疫苗对男孩产生明显保护作用的确切原因尚不清楚,可能是偶然发现。然而,由于该研究人群中男孩患病率更高,表明男孩更容易受到感染,因此对男孩的优先保护作用可能是由于反复接触受感染的沙蝇产生的更大的增强作用所致。应该尝试加强注射或其他佐剂来改善这种疫苗的潜在功效。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号